Patent Term Extension Application for CARDAMYST™ (etripamil). Patent No. 10,010,522 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-3813

Patent Term Extension Application for CARDAMYST™ (etripamil). Patent No. 10,010,522

Documents

Comments

Description

OPEN

Comment Period OpensApr 9, 2026

Type	Title	Posted	Comments	Status
Other	Patent Term Extension Application from Clark & Elbing, LLP (on behalf of Milestone Pharmaceuticals, Inc)	Apr 9, 2026	--

CDER

Patent Term Extension Application

Clark & Elbing, LLP

Milestone Pharmaceuticals, Inc.

CARDAMYST™ (etripamil)

Patent No. 10,010,522

OPEN